Kolexia
Mercier-Blas Anne Oncologie médicale
Mercier-Blas Anne
Oncologie médicale
C.h Fougeres
Fougères, France
42 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Métastase tumorale Tumeurs de l'ovaire Tumeurs colorectales Tumeurs du sein Carcinome épithélial de l'ovaire Tumeurs du foie Hypersensibilité Tumeurs du pancréas {{person.topmesh10.name}}

Collaborateurs

Voir plus
Le Scodan Romuald
Le Scodan Romuald
Clinique De La Cote D'emeraude, Saint-Malo, France
Hardy-Bessard Anne-Claire
Hardy-Bessard Anne-Claire
Gie Groupement D'imagerie Armoricaine, Plérin, France
Audemar Franck
Audemar Franck
Centre Hospitalier de la Côte Basque, Bayonne, France
Bendavid-Athias Cecile
Bendavid-Athias Cecile
Cabinet libéral, Cesson-Sévigné, France

Industries

Voir plus
Novartis
2 collaboration(s)
Dernière en 2020
MSD
1 collaboration(s)
Dernière en 2022
GSK
1 collaboration(s)
Dernière en 2020
Pfizer
1 collaboration(s)
Dernière en 2020

Dernières activités

Voir plus
MYCA: Phase Ib / II Trial Evaluating the Association Myocet ® - Carboplatine in Patients Having a Cancer of the Ovary in Relapse, Sensitive to the Platinum
Essai Clinique (ARCAGY/ GINECO GROUP)   05 septembre 2023
OSCAR: Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
Essai Clinique (Fédération Francophone de Cancérologie Digestive)   16 août 2023
Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial.
British journal of cancer   06 janvier 2022
Results of the VENUS study: Bevacizumab efficacy and safety in platinum-sensitive recurrent ovarian cancer (OC)—A real-life ambispective study.
2019 ASCO Annual Meeting I   26 mai 2019
Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial.
Gynecologic oncology   14 novembre 2018
FOLFIRINOX plus cetuximab (CET) or bevacizumab (BEV) in patients (pts) with initially unresectable colorectal liver metastases (CRLM) with BRAF mutated (mut) tumors: A subgroup analysis of the UNICANCER PRODIGE 14-ACCORD 21 (METHEP2) trial.
2018 ASCO Annual Meeting I   01 juin 2018
Induction chemotherapy (CT) with FOLFIRINOX or FOLFOX/FOLFIRI, plus cetuximab (CET) or bevacizumab (BEV) (by RAS status), in patients (pts) with primarily unresectable colorectal liver metastases (CRLM): Results of the randomized UNICANCER PRODIGE 14-ACCORD 21 (METHEP-2) trial.
2018 ASCO Annual Meeting I   01 juin 2018
Phase II trial evaluating the combination of eribulin (E)+ bevacizumab (BEV) as first line chemotherapy in patients with metastatic Her2-negative breast cancer (MBC): a GINECO group study
Abstract Book of the 41st ESMO Congress (ESMO 2016), 7-11 October 2016, Copenhagen, Denmark   01 octobre 2016
Non pegylated liposomal doxorubicin (npld, myocettm) + carboplatin (cb) in patients (pts) with ovarian cancer in late relapse (oclr): a phase 2 gineco study
Abstract Book of the 41st ESMO Congress (ESMO 2016), 7-11 October 2016, Copenhagen, Denmark   01 octobre 2016
FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study—Prodige 14 – ACCORD 21 (METHEP-2), a unicancer GI trial.
2016 ASCO Annual Meeting I   20 mai 2016